NSJ Bioreagents

EpCAM Antibody Overview

EpCAM Antibody reagents target epithelial cell adhesion molecule (EpCAM), also known as CD326, a type I transmembrane glycoprotein widely expressed on epithelial tissues. EpCAM functions as a calcium-independent cell adhesion molecule and is involved in cell proliferation, differentiation, migration, and intracellular signaling. In normal tissues, EpCAM maintains epithelial integrity and polarity, but in cancer, it frequently becomes overexpressed and functionally dysregulated.

EpCAM is expressed in the majority of human epithelial-derived cancers, including carcinomas of the colon, breast, prostate, ovary, pancreas, and lung. High levels of EpCAM often correlate with tumor progression, metastasis, and poor prognosis. Beyond oncology, EpCAM also marks progenitor and stem cells, playing critical roles in embryonic development and tissue regeneration. The EpCAM Antibody is therefore a valuable reagent in cancer biology, developmental biology, and clinical diagnostics. Meanwhile, the Epithelial Cell Adhesion Molecule Antibody provides broader coverage for applications across immunology, oncology, and translational research.

Why Choose EpCAM Antibodies from NSJ Bioreagents?

NSJ Bioreagents offers EpCAM Antibodies that are rigorously validated for immunohistochemistry, immunofluorescence, western blotting, ELISA, and flow cytometry. Each EpCAM Antibody undergoes strict quality control to ensure target specificity and minimal cross-reactivity, even in complex tissue environments where background staining can complicate results.

By selecting an EpCAM Antibody from NSJ Bioreagents, researchers gain reagents optimized for reproducibility and clarity. Our antibodies generate crisp membrane staining patterns in epithelial tissues, consistent protein detection in lysates, and reliable results across multiple experimental platforms. Detailed datasheets, suggested controls, and validated protocols ensure that researchers can confidently apply these tools in both research and diagnostic contexts.

Applications of EpCAM Antibodies

The EpCAM Antibody supports a wide array of applications in both research and clinical science.

1) Oncology and Tumor Biology

EpCAM Antibodies detect overexpression of EpCAM in carcinomas, including colorectal, breast, ovarian, and prostate cancers.
The EpCAM Antibody helps distinguish carcinomas from nonepithelial tumors and is frequently included in diagnostic panels.
Epithelial Cell Adhesion Molecule Antibody reagents are applied in biomarker discovery and prognosis research.

2) Cancer Stem Cells and Therapy Resistance

EpCAM Antibodies mark cancer stem cell populations that contribute to chemotherapy and radiotherapy resistance.
The EpCAM Antibody supports research into tumor recurrence and metastasis.
Epithelial Cell Adhesion Molecule Antibody tools are used to validate therapeutic targets in cancer stem cell–driven pathways.

3) Circulating Tumor Cells (CTCs) and Liquid Biopsy

EpCAM Antibodies are central to isolating CTCs from blood samples in liquid biopsy technologies.
The EpCAM Antibody supports non-invasive monitoring of tumor burden and therapeutic response.
Epithelial Cell Adhesion Molecule Antibody reagents aid in clinical studies of metastasis and disease progression.

4) Diagnostics and Clinical Pathology

EpCAM Antibodies are used in immunohistochemistry to confirm epithelial lineage in tumor biopsies.
The EpCAM Antibody provides reliable staining to differentiate metastatic carcinoma from lymphoma or sarcoma.
Epithelial Cell Adhesion Molecule Antibody tools are essential in pathology workflows where epithelial origin must be confirmed.

5) Developmental and Stem Cell Biology

EpCAM Antibodies track epithelial progenitor cells during embryogenesis.
The EpCAM Antibody validates epithelial differentiation in stem cell and organoid models.
Epithelial Cell Adhesion Molecule Antibody reagents contribute to regenerative medicine studies involving epithelial-derived tissues.

6) Translational and Clinical Research

EpCAM Antibodies are validated in biomarker-driven oncology clinical trials.
The EpCAM Antibody is applied to monitor novel immunotherapies, including CAR-T therapies and monoclonal antibodies targeting EpCAM.
Epithelial Cell Adhesion Molecule Antibody reagents support precision medicine approaches by stratifying patients based on biomarker expression.

Why Are EpCAM Antibodies Important?

EpCAM is one of the most widely studied epithelial markers due to its dual role in maintaining epithelial integrity and driving tumor biology. The EpCAM Antibody provides precise tools for detecting and quantifying EpCAM expression, while the Epithelial Cell Adhesion Molecule Antibody expands those applications across oncology, diagnostics, and translational medicine.

In basic biology, EpCAM Antibodies reveal how cell–cell adhesion contributes to epithelial tissue organization. In oncology, the EpCAM Antibody highlights tumor aggressiveness, metastatic potential, and cancer stem cell enrichment. In diagnostics, Epithelial Cell Adhesion Molecule Antibody reagents distinguish carcinomas from mesenchymal malignancies and metastatic lesions.

Clinically, EpCAM is emerging as a therapeutic target. Anti-EpCAM monoclonal antibodies and CAR-T therapies are in development, making EpCAM detection crucial for both patient selection and monitoring therapeutic efficacy. The EpCAM Antibody therefore bridges fundamental research with clinical innovation, ensuring reproducible results across discovery, diagnostics, and translational medicine.

Conclusion

EpCAM is a critical epithelial marker with wide-ranging roles in cancer biology, stem cell research, diagnostics, and translational medicine. The EpCAM Antibody equips researchers and clinicians with a validated reagent for detecting EpCAM expression, while the Epithelial Cell Adhesion Molecule Antibody provides expanded utility across clinical and biomedical applications. By combining rigorous validation with reproducibility, these antibodies remain indispensable for advancing epithelial biology and improving patient outcomes.